Myeloma and Second Primary Cancers

Authors:

Abstract
In December 2010, results from three randomized, phase 3 trials of treatments for multiple myeloma showed an excess of hematologic cancers among patients with multiple myeloma who received lenalidomide maintenance therapy (see Table 1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Researchers have been aware of second cancers after multiple myeloma — particularly acute myeloid leukemia and myelodysplastic syndromes — for more than four decades (Table 1 in the Supplementary Appendix). In 1979, Bergsagel et al. (see the Supplementary Appendix) found an increased risk of all forms of acute leukemia among 364 patients with multiple myeloma treated with low-dose melphalan (Table 1 in the Supplementary Appendix). Studies conducted after the introduction of high-dose melphalan followed by autologous stem-cell transplantation suggested that conventional chemotherapy before autologous stem-cell transplantation is a more likely contributing factor to myelodysplastic syndromes and acute myeloid leukemia than pretransplantation myeloablative therapy (Table 1 in the Supplementary Appendix).